• Proprietary, differentiated B cell targets engaged via antibody and CAR-T programs.
• KappaMab & LambdaMab only target malignant B cells, do not bind to normal immune cells.
o KappaMab plus RevDex Ph 2b in MM, data 2H20.
o Kappa CAR-T specific for target cells, no off tumour lysis. Capacity for dual-targeting with CD-19, BCMA, etc.
o LambdaMab in preclinical for amyloidosis.
• Raised $AUD8M since 2015; funded by current directors (56%) & 25 other primarily Australian investors.
Phase l or ll, Pre-Clinical Stage
Hematology, Immuno-Oncology, Immunotherapy
HaemaLogiX Pty. Ltd
Suite 204, Cicada Innovations, 4 Cornwallis St.
Eveleigh, NSW 2015